FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3069544664> ?p ?o ?g. }

• W3069544664 abstract "Background & Aim As part of the EU paediatric regulation, the paediatric use marketing authorisation (PUMA) was introduced, with an aim to stimulate research in existing compounds that are off-patent and/or to help transform known off-label use into authorised use. 1 However, success has been limited, with only a few products gaining a PUMA, such as Sialanar 320 micrograms/mL glycopyrronium (equivalent to 400 micrograms/mL glycopyrronium bromide). A distinct challenge to overcome in this area is the development of more ‘age appropriate formulations’, particularly with an excipient composition and load that is suitable for paediatric patients. This project aims to establish an excipient screening platform, supplemented with analytical characterisation of materials, which will act as a decision making tool to accelerate and de-risk the production of age appropriate paediatric medicines. Method To develop this excipient screening platform, a list of drugs that require an age appropriate formulation was produced using the ‘needs for paediatric medicines’ documents provided by the European medicines agency (EMA), 2 whilst common problematic excipients in paediatrics were identified using an EMA reflection paper. 3 Literature and prescribing data were also reviewed to ensure drugs selected would benefit from an age appropriate formulation. Differential scanning calorimetry (DSC) to determine compatibility of selected drugs with widely used excipients was carried out using a TA DSCQ200 instrument (TA Instruments, New Castle, DE) with TA Instruments Universal Analysis 2000 software. Data was collected under nitrogen atmosphere (50 mL min −1 ) using pierced flat-bottomed TZero aluminium pans (sample mass about 2 mg) and heating rate of 10 °C min −1 in the range from 50 to 400°C. For samples containing both the drug and an excipient, 1 mg of each was measured out and gently mixed with a spatula for one minute. Results The most common class of drugs identified as requiring age appropriate formulations were related to cardiovascular disorders and neurology, whilst the majority of drugs identified also exhibit poor aqueous solubilities. Some identified problematic excipients include ethanol, sodium benzoate and sorbitol; however, these excipients may still be used in paediatric formulations, as long as they are below certain concentrations (for example, ethanol concentration should not exceed 0.5% w/v for under 6 years old). Two drugs identified through the initial screening, carvedilol and nifedipine, were analysed by DSC, alone and then alongside starch from corn and starch 1500; the resulting DSC curves showed no changes in peak size, position (peak onset temperatures for nifedipine and carvedilol were observed at 173.2°C and 117.3°C, respectively) and shape, as well as no additional peaks, therefore suggesting compatibility between the tested samples. Conclusion This first phase of the development of an excipient screening platform will continue to scan several different excipients with selected active pharmaceutical ingredients (APIs) in order to create compatibility profiles. The excipient screening platform generated will accelerate and de-risk the production of age appropriate formulations, as it would allow screening for potential incompatibilities and acceptability, alongside informing formulation of appropriate oral paediatric dosage forms. References European Commission. State of Paediatric Medicines in the EU. 10 years of the EU Paediatric Regulation. COM (2017) 626. Available at: https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/2017_childrensmedicines_report_en.pdf Needs for paediatric medicines - European Medicines Agency [Internet]. 2019 [cited 28 June 2019]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/paediatric-medicines/needs-paediatric-medicines Reflection paper: formulations of choice for the paediatric population [Internet]. European Medicines Agency. 2019 [cited 28 June 2019]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf" @default.
• W3069544664 created "2020-08-24" @default.
• W3069544664 creator A5003212557 @default.
• W3069544664 creator A5040905542 @default.
• W3069544664 creator A5060976871 @default.
• W3069544664 creator A5076930417 @default.
• W3069544664 creator A5089270797 @default.
• W3069544664 date "2020-08-19" @default.
• W3069544664 modified "2023-09-23" @default.
• W3069544664 title "P23 Accelerating and de-risking the production of paediatric oral formulations" @default.
• W3069544664 doi "https://doi.org/10.1136/archdischild-2020-nppg.32" @default.
• W3069544664 hasPublicationYear "2020" @default.
• W3069544664 type Work @default.
• W3069544664 sameAs 3069544664 @default.
• W3069544664 citedByCount "0" @default.
• W3069544664 crossrefType "journal-article" @default.
• W3069544664 hasAuthorship W3069544664A5003212557 @default.
• W3069544664 hasAuthorship W3069544664A5040905542 @default.
• W3069544664 hasAuthorship W3069544664A5060976871 @default.
• W3069544664 hasAuthorship W3069544664A5076930417 @default.
• W3069544664 hasAuthorship W3069544664A5089270797 @default.
• W3069544664 hasBestOaLocation W30695446641 @default.
• W3069544664 hasConcept C2776654903 @default.
• W3069544664 hasConcept C2777239854 @default.
• W3069544664 hasConcept C38652104 @default.
• W3069544664 hasConcept C41008148 @default.
• W3069544664 hasConcept C71924100 @default.
• W3069544664 hasConcept C98274493 @default.
• W3069544664 hasConceptScore W3069544664C2776654903 @default.
• W3069544664 hasConceptScore W3069544664C2777239854 @default.
• W3069544664 hasConceptScore W3069544664C38652104 @default.
• W3069544664 hasConceptScore W3069544664C41008148 @default.
• W3069544664 hasConceptScore W3069544664C71924100 @default.
• W3069544664 hasConceptScore W3069544664C98274493 @default.
• W3069544664 hasLocation W30695446641 @default.
• W3069544664 hasOpenAccess W3069544664 @default.
• W3069544664 hasPrimaryLocation W30695446641 @default.
• W3069544664 hasRelatedWork W11907423 @default.
• W3069544664 hasRelatedWork W12053904 @default.
• W3069544664 hasRelatedWork W14899582 @default.
• W3069544664 hasRelatedWork W17113669 @default.
• W3069544664 hasRelatedWork W20860572 @default.
• W3069544664 hasRelatedWork W21347003 @default.
• W3069544664 hasRelatedWork W22279385 @default.
• W3069544664 hasRelatedWork W5600705 @default.
• W3069544664 hasRelatedWork W6853974 @default.
• W3069544664 hasRelatedWork W938527 @default.
• W3069544664 isParatext "false" @default.
• W3069544664 isRetracted "false" @default.
• W3069544664 magId "3069544664" @default.
• W3069544664 workType "article" @default.